Simpson-YapSDe BrouwerEKalincikT, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology2021; 97(19): e1870–e1885.
2.
SormaniMPSchiavettiIIngleseM, et al. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. eBioMedicine2022; 80: 104042.
3.
SchiavettiICordioliCStromilloML, et al. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Mult Scler2022; 28: 2106–2111.
4.
GombolayGYDuttMTyorW.Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: A systematic review/meta-analysis. Ann Clin Transl Neurol2022; 9(8): 1321–1331.
5.
AchironADolevMMenascuS, et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult Scler2021; 27(6): 864–870.
6.
AchironAMandelMDreyer-AlsterS, et al. Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study. J Neuroimmunol2021; 361: 577746.
7.
ZaloumSAWoodCHTankP, et al. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Mult Scler J2023; 29: 979–989.
8.
TallantyreECVickaryousNAndersonV, et al. COVID-19 vaccine response in people with multiple sclerosis. Ann Neurol2021; 91(1): 89–100.
9.
KlineovaSFarberRDeAngelisTL, et al. Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions—An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2). Mult Scler J2023; 29: 990–1000.
10.
Van KempenZLEStalmanEWSteenhuisM, et al. SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry2023; 94(4): 280–283.
